Wyeth earnings
This article was originally published in The Tan Sheet
Executive Summary
Worldwide Consumer Healthcare net revenue was flat at $598 mil. during the second quarter, Wyeth announces July 20. Net revenue for the division worldwide during the first six months of 2006 decreased 5% to $1.16 bil. when compared to the first six months of 2005. An increase in sales of Advil and Centrum vitamins helped offset losses caused by lower sales of Robitussin, Dimetapp and Advil Cold & Sinus, which resulted from increased retailer restrictions on pseudoephedrine-containing products, the company says. The earnings also reflect the loss of Solgar vitamin sales; the brand was divested to NBTY in the third quarter of 2005 (1"The Tan Sheet" Jan. 16, 2006, p. 13). Wyeth Nutrition's second-quarter net revenue increased 13% over the prior-year period to $300 mil...
You may also be interested in...
Solgar Brand Leads First-Quarter NBTY Sales Growth
NBTY's recently-acquired Solgar vitamin brand continues to drive the firm's sales, the company reported in a first-quarter earnings statement Jan. 9
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.